Research, Select, & Monitor Wednesday, April 24, 2019 7:51:15 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

Ticker Lookup
NuVasive Inc.$58.78$1.572.74%

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  NuVasive Inc. vs Diagnostic Substances

NUVASIVE is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.

Be they in the hardware development side or the chemical development side, these companies have the same goal; to increase the disease detection threshold and to increase the productivity of labs so more tests can be performed in less time. Each company tends to go about this goal in a different way. One company is involved heavily in gene testing and therapy, another is in manufacturing better isotopes to be used in nuclear medicine. Also, some companies have their hand in the home-testing fields for such things as Human Immunodeficiency Virus (HIV, the virus that causes AIDS) and other diseases.
 Totals Company Industry
  Sales: $1,101.7 Mil $12,335.8 Mil
  Market Cap: $2,941.7 Mil $67,477.2 Mil
  Analysts Recommendation: Hold Buy

 Averages Company Industry
  Historic Revenue: 7.0% 17.5%
  Estimated Revenue: 4.4% 6.4%
  Historic Earnings: 16.8% 158.7%
  Estimated Earnings: 7.0% 16.1%
  Stock Price (1 Year): 8.2% 64.5%
  Cash per Share: 52.3% 65.1%
  Dividend: N/A N/A
  Trailing PE: N/A N/A
  Forward PE: 22.5 37.7
  Price-to-Sales: 2.7 N/A
  Price-to-Book: 3.5 (91.6)
  Dividend Yield: N/A N/A
  Market Cap: $2,941.7 Mil $3,373.9 Mil
  Net Margin: 1.1% (1,797.8%)
  Gross Margin: 71.8% 53.7%
  Return on Equity: .0 (.5)
  Return on Assets: .0 (.1)
  Balance Sheet
  Current Ratio: 3.4 4.5
  Quick Ratio: 1.9 3.9
  Cash Ratio: .7 3.2
  Debt-to-Equity: 1.0 5.3
  Interest Coverage: (.2) .8
  Relative-Strength Index: 56.4 N/A

 Other companies in Diagnostic Substances Price Market Cap
  Edwards Lifesciences Corp.  (EW) $180.98 $37,833.9 Mil
  IDEXX Laboratories, Inc.  (IDXX) $224.45 $19,354.3 Mil
  DexCom Inc  (DXCM) $118.03 $10,485.8 Mil
  Wright Medical Group Inc.  (WMGI) $28.81 $3,603.6 Mil
  Neogen Corp.  (NEOG) $57.64 $3,014.1 Mil

Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results, the logo, and News Selects are trademarks of
Copyright © 1998 - 2019 All rights reserved.